![]() The Chadds Ford-area office space Incyte is leasing reportedly has been vacant since late 2012 when former tenant Endo Pharmaceuticals moved to Malvern, Pennsylvania.Įndo, which sells the pain medication Percocet, was launched in 1997 by three former DuPont Merck executives who bought their former employer’s suite of generic pain drugs for $277 million.įour years later, DuPont sold its pharmaceutical business to Bristol-Myers Squibb for $7.8 billion. The company, which went public in 1993, has added about 200 jobs in recent years and now employs roughly 680. ![]() Widely hailed as one of Delaware’s biggest success stories in recent years, Incyte expects to end 2015 with more than $500 million in net product revenue from sales of Jakafi, the first and only drug approved in the United States to treat patients with two rare blood cancers – myelofibrosis and polycythemia vera. The Incyte employees moving to Chadds Ford area will return to Delaware once the new building is finished in late 2017.Ĭatalina said additional work also is planned for the former Wanamaker building, which underwent $35 million in renovations last year. Soon after, the company plans to begin building a 154,000-square-foot, four-story office building and 473-space parking garage on the property. The transaction is expected to close on April 1. Capano Jr., owner of the Wannamaker building property, to acquire the entire 16.7-acre parcel for about $80 million. The rapidly growing biopharma company inked a purchase agreement this year with Louis J. "We are working to consolidate the company on the same campus, so the temporary move allows us to start bringing people together." ![]() "Both our headquarters and the commercial and medical affairs space are nearing capacity," Loveman said. Those employees, along with about 200 workers from Incyte’s headquarters, will be relocated to the Chadds Ford office space in early 2016. medical affairs and marketing offices, meanwhile, work out of two floors in the former Rollins Building at 2200 Concord Pike. The building houses about 500 workers in Incyte’s corporate offices, along with all of its drug discovery functions. ![]() Incyte signed a 15-year lease in 2013 for its current 191,000-square-foot headquarters in the former John Wannamaker department store. “We certainly don’t want anyone to think otherwise because it’s not the case.”Ĭhief Executive Officer Hervé Hoppenot will maintain offices in both locations, while the Alapocas site will remain the official company headquarters, she said. “Rest assured it’s only a temporary thing,” she said. Some media sources on Friday erroneously reported Incyte will move its corporate operations to Chadds Ford, a claim Loveman strongly refuted. “Unfortunately, we were not able to find anything close to our headquarters that provided the amount of office space we need for the duration we need it.” “We looked at a lot of different places, including some potential options in Delaware,” she said. ![]() The office space – totaling 111,500 square feet – will house roughly 300 Incyte employees for nearly two years while the company completes construction of a new building next to its existing headquarters at 1801 Augustine Cut-Off in Alapocas, according to company spokeswoman Catalina Loveman. The buildings were previously occupied by Endo Pharmaceuticals, another drugmaker that traces its origins back to DuPont Co. The fast-growing Delaware pharmaceutical company confirmed Friday that it has signed a lease for two buildings in the Painter’s Crossing Office Campus near Chadds Ford. will temporarily move about half of its Delaware workforce over the state line into Pennsylvania early next year. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |